

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Ikeda, et al.)	Group Art Unit Unknown
)	
Appl. No.	:	Unknown)	
)	
Filed	:	Herewith)	
)	
For	:	METHOD FOR EVALUATING)	
		DRUG SENSITIVITY)	
)	
Examiner	:	Unknown)	
)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Preliminary to examination on the merits, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please replace the paragraph beginning at page 3, line 11, with the following rewritten paragraph:

-- Fig. 1A to Fig. 1D are evaluation results for sensitivity to morphine and (-)-U-50488. --

Please replace the paragraph beginning at page 17, line 13, with the following rewritten paragraph:

-- The results of the tail-flick and hot-plate tests performed for morphine (Mor) induced analgesic effect are shown in Fig. 1A and Fig. 1B, and the results of the open-field test performed for morphine-induced hyperactivity are shown in Fig. 1C. Further, the result of the investigation for whether the CXBK μ -OR gene induces reduction of analgesic effects of (-)-U-50488 (U-50), which is a selective κ -agonist, in CXBK mice are shown in Fig. 1D. The values mentioned in Fig. 1A to Fig. 1D are represented as average \pm SEM. Each group consisted of 10 animals for Fig. 1A to Fig. 1C, and each group consisted of 6 animals for Fig. 1D. --

IN THE CLAIMS:

Please add the following claims:

7. (New) The method according to Claim 1, wherein the drug is selected from the group consisting of analgesics, carcinostatics, anti-allergy agents, hypotensors, diuretics and anesthetics.

8. (New) The method according to Claim 2, wherein the drug is selected from the group consisting of analgesics, carcinostatics, anti-allergy agents, hypotensors, diuretics and anesthetics.

9. (New) The method according to Claim 1, wherein the gene is a gene of drug receptors, or a gene of enzymes involved in metabolism of drugs.

10. (New) The method according to Claim 2, wherein the gene is a gene of drug receptors, or a gene of enzymes involved in metabolism of drugs.

IN THE DRAWINGS:

As stated in the attached Request for Approval of Drawing Changes, Applicant has requested to amend drawing number to indicate separately each drawing, as shown in the attached copy of the figure wherein the correction is indicated with red ink.

REMARKS

Claims 7-10 have been added by the current amendment. Support for Claims 7 and 8 can be found on page 3, line 24-26. Support for Claims 9 and 10 can be found on page 4, line 16-18. The specification and the drawing have been amended to comply with the U.S. practice. As such, no new matter has been added. Entry of the amendments is respectfully requested.

Should there be any questions concerning this application, the Examiner is respectfully invited to contact the undersigned at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 11, 2002

By:



Daniel E. Altman

Registration No. 34,115

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(949) 760-0404

VERSION WITH MARKINGS TO SHOW CHANGES MADE

IN THE SPECIFICATION:

Paragraph beginning at line 11 of page 3 has been amended as follows:

Fig. 1A to Fig. 1D ~~shows~~are evaluation results for sensitivity to morphine and (-)-U-50488.

Paragraph beginning at line 13 of page 17 has been amended as follows:

The results of the tail-flick and hot-plate tests performed for morphine (Mor) induced analgesic effect are shown in Figs. 1, A and B ~~Fig. 1A and Fig. 1B~~, and the results of the open-field test performed for morphine-induced hyperactivity are shown in Fig. 1, C. Further, the result of the investigation for whether the CXBK μ -OR gene induces reduction of analgesic effects of (-)-U-50488 (U-50), which is a selective κ -agonist, in CXBK mice are shown in Fig. 1, D. The values mentioned in Fig. 1A to Fig. 1D are represented as average \pm SEM. Each group consisted of 10 animals for Fig. 1A to Fig. 1C, and each group consisted of 6 animals for Fig. 1D.

IN THE CLAIMS:

Claims 7-10 have been added.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Ikeda, et al.)	Group Art Unit Unknown
)	
Appl. No.	:	Unknown)	
)	
Filed	:	Herewith)	
)	
For	:	METHOD FOR EVALUATING)	
		DRUG SENSITIVITY)	
)	
Examiner	:	Unknown)	
)	

REQUEST FOR APPROVAL OF DRAWING CHANGES

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.123, Applicant requests approval of the following drawing change shown in red on the attached copy of Figure 1:

In Figure 1, please replace drawing numbers A, B, C and D with drawing numbers Fig. 1A, Fig. 1B, Fig. 1C and Fig. 1D, respectively.

REMARKS

The amendment to the drawing requested herein is for changing drawing number to indicate separately each drawing. The amendment does not raise any new matter, and Approval of this amendment is respectfully requested.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: February 11, 2002

By:



Daniel E. Altman

Registration No. 34,115

Attorney of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(949) 760-0404

Fig. 1A




Fig. 1B




Fig. 1C





Fig. 1D



~~Fig. 1~~